JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Regulation of inflammatory mediators in lipopolysaccharide-stimulated RAW 264.7 cells by 2''-hydroxy-3''-en-anhydroicaritin involves down-regulation of NF-kappaB and MAPK expression.

2''-hydroxy-3''-en-anhydroicaritin, a flavone, was isolated from the Chinese medicinal herb Epimedium brevicornum for the first time. In our previous study, we have carried out a screening program to identify the anti-inflammatory potentials of 2''-hydroxy-3''-en-anhydroicaritin. In the present study, we further found that this compound regulated lipopolysaccharide (LPS)-induced levels of nitric oxide (NO), and prostaglandin E(2) (PGE(2)) (**p<0.01 or *p<0.05), and reduced levels of iNOS and COX-2 in RAW 264.7 macrophages in a concentration-dependent manner. We further investigated signal transduction mechanisms to determine how 2''-hydroxy-3''-en-anhydroicaritin affects RAW264.7 macrophages pretreated with 0.5, 2.5, or 12.5mg/L of 2''-hydroxy-3''-en-anhydroicaritin 1h prior to treatment with 1mg/L of LPS. Thirty minutes later, cells were harvested and mitogen-activated protein kinases (MAPK) activation and I kappaB alpha were measured by western blotting. Alternatively, the macrophages were fixed and nuclear factor-kappaB (NF-kappaB) activation was measured by immunocytochemical analysis. Signal transduction studies showed that the flavone significantly inhibited extracellular signal-regulated kinase (ERK), p38, and c-jun NH2-terminal kinase (JNK) phosphorylation protein expression. The flavone also inhibited p65-NF-kappaB translocation into the nucleus by I kappaB alpha degradation. Therefore, 2''-hydroxy-3''-en-anhydroicaritin may inhibit LPS-induced production of inflammatory cytokines by blocking NF-kappaB and MAPK signaling in RAW264.7 cells.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app